Connect
MJA
MJA

Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia

Nigel Strauss
Med J Aust 2017; 206 (11): 468-469. || doi: 10.5694/mja17.00081

Contemporary research suggests potential benefits of psychedelic drugs in treatment-resistant depression and terminally ill patients

Despite their stigmatisation, psychedelic drugs are once again being clinically researched in Europe and North America. This long-awaited renaissance is showing very promising results and, unlike the pioneering research that occurred before these drugs were outlawed over 30 years ago, the current methodology is rigorous and of a very high standard.

  • Nigel Strauss

  • Millswyn Clinic, Melbourne, VIC

Correspondence: drnigel@bigpond.net.au

Acknowledgements: 

I thank Martin Williams for his assistance in the preparation and revision of this manuscript.

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.